Filing Details

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment 1) Under the Securities Exchange Act of 1934(Name of Issuer) AXSOME THERAPEUTICS INC (Title of Class of Securities) Common Stock (CUSIP Number) 05464T104 (Date of Event Which Requires Filing of this Statement) December 31, 2017 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ]Rule 13d-1(b) [ X ]Rule 13d-1(c) [ ]Rule 13d-1(d) CUSIP No. 05464T104 1.Names of Reporting Persons. Laurence W.Lytton 2. Check the Appropriate Box if a Member of a Group (See Instructions) a).......................................................................... (b).......................................................................... 3.SEC Use Only 4.Citizenship or Place of Organization USA 5.Sole Voting Power 966,190 6.Shared Voting Power 16,500 7.Sole Dispositive Power 966,190 8.Shared Dispositive Power 16,500 9.Aggregate Amount Beneficially Owned by Each Reporting Person 982,690 10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)................................. 11.Percent of Class Represented by Amount in Row (9) 4.2% (1) Based on 23,671,301 shares outstanding as of November 3, 2017 as reported in the September 30, 2017 10-Q. 12.Type of Reporting Person (See Instructions) IN Item 1. (a)Name of Issuer AXSOME THERAPEUTICS INC (b)Address of Issuer's Principal Executive Offices 25 Broadway, 9th Fl New York, New York